Subjects with impaired glucose tolerance and/or impaired fasting glucose Nutritional, Metabolic, Endocrine Glucose Tolerance , Fasting Glucose
Conditions
Interventions
The following will be performed in each subject:
1. A modified euglycaemic hyperglycaemic clamp with arginine stimulation (After an euglycaemic clamp [120 minutes, 5 mmol/L], there is an hour rest pe
Sponsors
VU University Medical Center, Diabetes Center (The Netherlands)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female subjects (aged 35-70 years) 2. Impaired Fasting Glucose (IFG; plasma glucose > = 6.1 and = 5.6 and < 7.0 mmol/l) and a family history of Diabetes Mellitus type two (DM2; i.e. first and second degree [i.e. grandparents] relatives) and/or 4. Impaired Glucose Tolerance (IGT; 2-hour plasma glucose during 75 g Oral Glucose Tolerance Test [OGTT] 7.8-11.1 mmol/l)
Exclusion criteria
Exclusion criteria: 1. Known diabetes 2. History or present liver, exocrine pancreatic or renal disease 3. Drug-/alcohol abuse 4. Acute cardiovascular disease <3 months prior to screening 5. Malignant disease 6. Claustrophobia and metal implants or pacemakers (MRI) 7. Lack of capacity to understand the aim of the research 8. Use of the following: 8.1. Glucocorticoids 8.2. Cytostatic drugs 8.3. Thiazolidinediones 8.4. Metformin 8.5. Oral contraceptives 8.6. Fibrates 8.7. Anti epileptic drugs 8.8. Centrally acting drugs for neurologic and/or psychiatric indications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Triglyceride content of the human pancreas in vivo assessed using non-invasive 1H-MRS 2. Relation between pancreatic triglyceride accumulation and beta-cell function 3. Relation between triglyceride accumulation in the pancreas and other fat compartments within the abdomen | — |
Secondary
| Measure | Time frame |
|---|---|
| No secondary outcome measures | — |
Countries
Netherlands
Outcome results
None listed